The day in conversation for 2026-11-03

discussion

Transcript

The discussion: Tom: That mediation analysis result regarding the monoclonal antibody therapy is interesting because if you only count the reduction in hospitalization risk when viral RNA is left-censored by assay limits, are we really missing a significant pathway, or is that bias inherent to the measurement process itself? Jane: I think it points toward a specific limitation in applying standard structural equation modeling here; the fractional imputation approach sounds promising for handling that censoring, but what assumptions about the relationship between viral load and clinical outcome are they making about the underlying distribution? Lu: From my perspective on mediation, if you’re using an EM algorithm to reduce bias, does that imply a specific functional form for the effect of the mediator itself, or is it agnostic to non-linear relationships in the pathway? Meng: I'm curious how that ties into what we saw last week with those sparse representation learning papers; is there any overlap in how you’re treating missing data versus how they are handling latent variable estimation when the observations themselves are incomplete due to assay limits? Lalam: If we look at the Beyond Vintage Rotation work, the oracle inference property sounds powerful, but that property relies on assuming

More episodes

← Home